Lista de obras - Barbara Peter - Dominio Público Uruguay

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

artículo científico publicado en 2012

Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage

artículo científico publicado en 2014

Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms

artículo científico publicado en 2019

Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.

artículo científico publicado en 2008

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

artículo científico publicado en 2017

Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells

scientific article published on 13 August 2019

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

artículo científico publicado en 2009

H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells

artículo científico publicado en 2010

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

artículo científico publicado en 2015

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA

artículo científico publicado en 2014

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia

artículo científico publicado en 2014

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

artículo científico publicado en 2009

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

artículo científico publicado en 2010

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

artículo científico publicado en 2010

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives

scientific article published on 13 July 2018

Midostaurin: a magic bullet that blocks mast cell expansion and activation

artículo científico publicado en 2017

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. ⬇️

artículo científico publicado en 2012

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

artículo científico publicado en 2010

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

artículo científico publicado en 2011

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis

scientific article published on 05 July 2018

Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells

artículo científico publicado en 2015

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V

artículo científico publicado en 2013

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

artículo científico publicado en 2016

Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.

artículo científico publicado en 2008

The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells

artículo científico publicado en 2012

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

artículo científico publicado en 2017

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

artículo científico publicado en 2018

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils

artículo científico publicado en 2012

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

artículo científico publicado en 2013

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

scientific article published on 14 September 2015

Lista de obras de Barbara Peter

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage

Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms

Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives

Midostaurin: a magic bullet that blocks mast cell expansion and activation

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. ⬇️

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis

Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.

The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition